GLP-1s Are Cutting My AUD Patients’ Hospitalizations. Trial Designers Need to Know Why.
A Lancet Psychiatry study links GLP-1 receptor agonists to fewer AUD and SUD hospitalizations—but the post-discontinuation signal demands a...
GLP-1 Agonists Are Quietly Reducing Addiction Hospitalizations, But Only While Patients Take Them
A Lancet Psychiatry study shows GLP-1 agonists cut AUD and SUD hospitalizations, but the protection fades after stopping —...
The Serotonin Signal Hiding in Plain Sight Across Two Rapid-Acting Depression Treatments
A Bayesian PET re-analysis finds ketamine and ECT both upregulate 5-HT1B receptors, pointing to a shared biomarker that TRD...
The Patients We’ve Been Afraid to Treat: PTSD, Psychosis, and What the STAR Trial Just Proved
The STAR trial enrolled 305 psychosis-PTSD patients clinicians long excluded from trauma therapy. The safety and efficacy data should...
What a Single-Dose Synthetic Psychedelic Teaches Us About the Limits of Our TRD Trial Designs
A JAMA Psychiatry trial of inhaled mebufotenin in TRD shows rapid antidepressant response, and exposes critical gaps in how...
What Semaglutide’s Fentanyl Data Should Mean for How We Design the Next OUD Trial
New preclinical data shows semaglutide cuts fentanyl self-administration in rats, and raises hard questions about OUD trial design for...
What a 26-Trial Ketamine Meta-Analysis Gets Right, and What It Still Can’t Capture
A JAMA Psychiatry meta-analysis of 26 RCTs confirms ketamine's acute antidepressant effect. Here's what 1,166 trial patients don't show...
The Patients We Told Ourselves Were Too Fragile
The STAR trial proves trauma-focused CBT is safe and effective in psychosis/PTSD patients—a dual-diagnosis population psychiatry has systematically excluded…
The Patient Tearing Up My Waiting Room Is Why Cebranopadol Matters
Tris Pharma presents cebranopadol (TRN-228) dual NOP/MOP data at CPDD 2026. For patients with comorbid chronic pain and OUD,...
ADHD Dosing Has Two Failure Modes, and Trials Are Designed to Miss Both
A Lancet Psychiatry network meta-analysis of ADHD pharmacotherapy exposes therapeutic inertia and uncritical dose escalation as twin hazards—with direct…